Logo
x

Search

Subscribe Now

Enliven Therapeutics

Enliven Therapeutics Reports the PoC Data from the P-I Study of ELVN-001 as a Treatment of Chronic Myeloid Leukemia

Enliven Therapeutics Reports the PoC Data from the P-I Study of ELVN-001 as a Treatment of Chronic Myeloid Leukemia

  • April 12, 2024
Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M

Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M

  • October 14, 2022
PharmaShots Weekly Snapshots (October 10 - 14, 2022)

PharmaShots Weekly Snapshots (October 10 - 14, 2022)

  • October 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.